Magnesium in Aneurysmal Subarachnoid Hemorrhage.

Magnesium in Aneurysmal Subarachnoid Hemorrhage (MASH II), a phase III clinical trial.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON20670

Enrollment

1200

Registered

2005-07-06

Start date

2006-01-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Magnesium sulfate 64 mmol/d (or placebo) is started intravenously as soon as possible after informed consent and continued until 20 days after the hemorrhage.

Eligibility

Inclusion criteria

Inclusion criteria: Aneurysmal subarachnoid hemorrhage.

Exclusion criteria

Exclusion criteria: 1. Renal failure (creatinin > 150), 2. age < 18 jaar, 3. weight < 50 kg, 4. no informed consent, 5. death is imminent.

Design outcomes

Primary

Measure	Time frame
Poor outcome (dependence or death) 3 months after the subarachnoid hemorrhage (Rankin 0-3 versus Rankin 4-5, or death) as assessed with the modified Rankin scale during a telephone interview. Dependence will be defined as a Rankin score > 3.	—

Secondary

Measure	Time frame
No symptoms 3 months after the subarachnoid hemorrhage (Rankin 0 versus Rankin 1-5 or death). Global change in Rankin score.	—

Contacts

Public ContactWalter M. Bergh, van den

University Medical Center Utrecht (UMCU), Department of Neurology, room G03.228 P.O. Box 85500

w.m.vandenbergh@neuro.azu.nl+31 (0)30 2508350

Outcome results